Overview

Properties

  • FormLiquid
  • Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
  • Storage bufferPreservative: 0.02% Sodium Azide
    Constituents: 0.5% BSA, 0.5mg/ml Tris, pH 7.3
  • Concentration information loading...
  • PurityIgG fraction
  • Purification notesPurified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
  • ClonalityPolyclonal
  • IsotypeIgG
  • Research areas

Associated products

Applications

Our Abpromise guarantee covers the use of ab2230 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB
  • Application notesWB: Use at a concentration of 1 - 4 µg/ml. Predicted molecular weight: 51 kDa. Approx 70kDa band seen in Daudi lysate.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionFunctions as a central linker protein that bridges kinases associated with the B-cell receptor (BCR) with a multitude of signaling pathways, regulating biological outcomes of B-cell function and development. Plays a role in the activation of ERK/EPHB2, MAP kinase p38 and JNK. Modulates AP1 activation. Important for the activation of NF-kappa-B and NFAT. Plays an important role in BCR-mediated PLCG1 and PLCG2 activation and Ca(2+) mobilization and is required for trafficking of the BCR to late endosomes. However, does not seem to be required for pre-BCR-mediated activation of MAP kinase and phosphatidyl-inositol 3 (PI3) kinase signaling. May be required for the RAC1-JNK pathway. Plays a critical role in orchestrating the pro-B cell to pre-B cell transition (By similarity). Plays an important role in BCR-induced B-cell apoptosis.
    • Tissue specificityExpressed in B-cell lineage and fibroblast cell lines (at protein level). Highest levels of expression in the spleen, with lower levels in the liver, kidney, pancreas, small intestines and colon.
    • Involvement in diseaseDefects in BLNK are the cause of agammaglobulinemia type 4 (AGM4) [MIM:613502]. It is a primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B cells due to an early block of B-cell development. Affected individuals develop severe infections in the first years of life.
    • Sequence similaritiesContains 1 SH2 domain.
    • Post-translational
      modifications
      Following BCR activation, phosphorylated on tyrosine residues by SYK and LYN. When phosphorylated, serves as a scaffold to assemble downstream targets of antigen activation, including PLCG1, VAV1, GRB2 and NCK1. Phosphorylation of Tyr-84, Tyr-178 and Tyr-189 facilitates PLCG1 binding. Phosphorylation of Tyr-96 facilitates BTK binding. Phosphorylation of Tyr-72 facilitates VAV1 and NCK1 binding. Phosphorylation is required for both Ca(2+) and MAPK signaling pathways.
    • Cellular localizationCytoplasm. Cell membrane. BCR activation results in the translocation to membrane fraction.
    • Information by UniProt
    • Database links
    • Alternative names
      • AGM4 antibody
      • B cell adapter containing SH2 domain protein antibody
      • B cell adapter containing Src homology 2 domain protein antibody
      • B cell adaptor containing SH2 domain antibody
      • B cell linker antibody
      • B cell linker protein antibody
      • B cell-specific adaptor protein antibody
      • B-cell activation antibody
      • B-cell adapter containing a SH2 domain protein antibody
      • B-cell adapter containing a Src homology 2 domain protein antibody
      • B-cell linker protein antibody
      • BASH antibody
      • Bca antibody
      • BLNK antibody
      • BLNK s antibody
      • BLNK_HUMAN antibody
      • Cytoplasmic adapter protein antibody
      • Ly 57 antibody
      • Ly57 antibody
      • Lymphocyte antigen 57 antibody
      • Lyw 57 antibody
      • Lyw57 antibody
      • MGC111051 antibody
      • SH2 domain-containing leukocyte protein, 65-KD antibody
      • SLP 65 antibody
      • SLP-65 antibody
      • SLP65 antibody
      • Src homology [SH2] domain-containing leukocyte protein of 65 kD antibody
      • Src homology 2 domain containing leukocyte protein of 65 kDa antibody
      • Src homology 2 domain-containing leukocyte protein of 65 kDa antibody
      see all

    Anti-BLNK antibody images

    • Anti-BLNK antibody (ab2230) at 4 µg/ml + Cell lysate prepared from human Daudi cells at 35 µg
      Developed using the ECL technique

      Predicted band size : 51 kDa
      Observed band size : 70 kDa (why is the actual band size different from the predicted?)


      Primary incubated for 1 hour.
    • All lanes : Anti-BLNK antibody (ab2230) at 1 µg/ml

      Lane 1 : Cell lysate prepared from HEK293 mock transfected cells
      Lane 2 : Cell lysate prepared from HEK293 overexpressing BLNK


      Predicted band size : 51 kDa
      Observed band size : 50 kDa (why is the actual band size different from the predicted?)

    References for Anti-BLNK antibody (ab2230)

    ab2230 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab2230.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"